What is Anadrol?
Anadrol (Oxymetholone, A50) is one of the strongest oral mass steroids. It delivers very fast, large gains in strength and weight but comes with a lot of water retention and, as a 17a-alkylated substance, is strongly liver-loading. Clinically oxymetholone is approved to treat anemia.
This information is for research and educational purposes only. No medical advice.
Comparison
Oral steroids compared
Steroids as tablets and as oil, as stated in the TPD lexicon. Tap a card to open its entry.
Simplified: all act via the androgen receptor and differ in form, strength and liver strain. Oxymetholone and methandienone are 17-alpha-alkylated. 31
How it works
Oxymetholone activates the androgen receptor and strongly raises protein synthesis and erythropoiesis - hence the clinical use in anemia. It does not aromatize but still has estrogen-like effects (water retention, gyno risk) via another pathway, which is why classic aromatase inhibitors do not help here.
Where it acts
Where oxymetholone acted in studies
Tap a point or a card. Colour = androgen receptor, grey = observed in studies.
- Skeletal muscle
Fat-free mass and strength rose, depending on the amount (older men, dialysis)4
AR - Blood
Approved for anaemia caused by too little red blood cell production3
AR - Liver
Liver enzymes rose, up to 35 percent with ALT above five times baseline5
Observed in trials - Fat tissue
Trunk fat fell by up to 2.2 kg in 12 weeks4
Observed in trials - Heart and blood lipids
HDL cholesterol fell markedly at both study levels4
Observed in trials - Testes and hormone axis
Anabolic steroids suppress the body's own testosterone and gonadotropin production, sometimes for months2
Observed in trials
Targets in the ChEMBL database13
Compound CHEMBL1200585: one recorded mechanism, agonist with direct binding to the human receptor.
- Gene
- AR
- UniProt
- P10275
- ChEMBL
- CHEMBL1871
- Action
- Agonist, direct binding
Use and dosing
Dosing
Dosing, titration and syringe
Loading the dosing information …
- Getting started and stepping up, drawn as a staircase
- Units on the U-100 syringe for every step
- How long one vial lasts
What the research shows
Oxymetholone has a real clinical history as an anemia drug. The AAS pharmacology (Kicman 2008, Hartgens & Kuipers 2004) classes the fast mass and strength gains of oral 17a-alkylated steroids.
Study results
What the trials measured
Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.
Fat-free mass and trunk fat after 12 weeks4
31 men aged 65 to 80, change in kg
Two study levels against placebo. The gain depended on the amount. HDL cholesterol fell markedly at both levels and the liver enzyme ALT rose at the higher level.
Maximum strength after 12 weeks4
Change in maximum strength in percent
Values from the abstract. The spread was wide (lat pull-down at the higher level plus or minus 21 percentage points). Without strength training, community-dwelling men.
Weight and body cell mass5
Phase 3 trial, 89 women and men, gain in kg
The highest level gave no more gain but more liver strain. Appetite and well-being improved. An earlier open study saw an average gain of 8.2 kg at the peak.
Research status
Where the research stands
ClinicalTrials.gov lists no trial with oxymetholone, not under the brand names either. The WHO search portal, which pools the other registries, lists one completed trial in dialysis (ISRCTN). Four published controlled trials without a registry number come on top. All used oxymetholone as a tablet. As of 26 Oct 2026. 1211
- Preclinical Hardly any studies on kinetics and tolerability before approval
- Phase 1 no registered trial
- Phase 2 no registered trial
- Phase 3 1 trial, 1 completed
- Approval as a tablet for anaemia
Show all 5 trials on a timelineHide timeline
Hengge 2003 · no registry number · 89 participants, published 2003.
Publication: Hengge et al., AIDS, 2003
Bacigalupo 1993 · no registry number · 134 participants, published 1993.
Publication: Bacigalupo et al., British Journal of Haematology, 1993
Schroeder 2003 · no registry number · 31 participants, published 2003.
Publication: Schroeder et al., American Journal of Physiology: Endocrinology and Metabolism, 2003
Supasyndh · ISRCTN41591818 (ISRCTN) · 43 participants, started Jan 2007, primary endpoint reached Jan 2008.
Registry entry ↗ · Results: Supasyndh et al., Clinical Journal of the American Society of Nephrology, 2013
Aramwit 2010 · no registry number · 24 participants, published 2010.
Publication: Aramwit et al., International Journal of Clinical Pharmacology and Therapeutics, 2010
Bar: start to primary endpoint (planned for running trials), for published trials without a stated period the year of publication. Green = completed, blue = progress until 26 Oct 2026.
Side effects
- Liver: 17a-alkylated, strong - short cycles, liver support.
- Water/gyno: estrogen-like effects despite no aromatization - classic AIs do not help.
- Blood pressure: rises markedly from water retention.
- Lipids: HDL drops strongly.
- HPTA suppression - PCT topic.
Tolerability
Liver enzymes in the HIV trial
Out of 100 participants, in how many the liver enzyme ALT rose above five times baseline.
| Event | Placebo | Twice daily | Three times daily (highest study dose, 150 mg per day) |
|---|---|---|---|
| ALT above five times5 | 0% | 27% | 35% |
In older men ALT also rose markedly at the higher level and HDL fell at both levels. Reviews name jaundice from bile congestion as the most important liver damage, less often blood-filled liver cysts and liver tumours, plus rising blood pressure.5432
Storage
Store dry and cool, protected from light. Out of reach of children.